Epogen and Procrit are specialty medications used to treat anemia caused by chronic kidney disease (CKD) or chemotherapy, but they don’t come cheap.
Is Epogen an ESA?
These drugs are given by injection (shot) and work by stimulating the production of more red blood cells. These cells are then released from the bone marrow into the bloodstream. There are two ESAs on the U.S. market: epoetin alfa (Procrit,® Epogen®), and darbepoietin alfa (Aranesp®).
Are Epogen and Procrit the same?
Epogen and Procrit are both epoetin alfa, but they are marketed by two different pharmaceutical companies. The FDA approved epoetin alfa in June 1989.
Is Epogen FDA approved?
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
Is Vyvanse a formulary drug?
Vyvanse (lisdexamfetamine) is non-formulary, but available to most beneficiaries at the non-formulary cost share.
How is Retacrit different from Epogen?
Retacrit cannot be interchanged with Epogen at the pharmacy level; the physician must specifically order Retacrit. Retacrit (epoetin alfa-epbx), from Hospira, and Epogen, (epoetin alfa), from Amgen, are both erythropoiesis-stimulating agents (ESA) used to help improve red blood cell production.
When is EPO indicated?
Erythropoietin is used in many clinical settings. The most common use is in people with anemia (low blood count) related to kidney dysfunction. When the kidneys are not properly functioning, they produce less than normal amounts of erythropoietin, which can lead to low red blood cell production, or anemia.
Is Epogen same as epoetin?
Epoetin alfa (marketed as Procrit and Epogen) and darbepoetin alfa (marketed as Aranesp), are manufactured by Amgen, Inc.
Will Tricare approve Vyvanse?
What is the ESA REMS for Epogen/Procrit?
The ESA REMS for Epogen/Procrit and Aranesp, approved in February 2010, jointly fall under a common implementation program, the ESA Apprise Oncology Program. The ESA REMS consisted of a Medication Guide, communication plan, elements to assure safe use, implementation system, and a timetable for submission of assessments of the REMS.
What is the REMS program?
The REMS was approved in 2010. Under the REMS program, referred to as the ESA APPRISE Oncology Program, healthcare providers that prescribed and/or dispensed Aranesp to patients with cancer and hospitals that dispensed Aranesp to patients with cancer were required to enroll and become certified in the ESA REMS.
What is epepogen used to treat?
Epogen/Procrit was approved on June 1, 1989 for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis and on April 1, 1993 for the treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy.
Do you have to be a prescriber to dispense Epogen/Procrit?
Prescribers will no longer be required to complete a Patient and Healthcare Provider Acknowledgement Form for each patient with cancer before the new Epogen/Procrit treatment course. Hospitals that dispense Epogen/Procrit to patients with cancer will no longer be required to enroll and become certified to dispense Epogen/Procrit.
